- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor Which conditions qualify? The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
- News News
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Reports 2020 State of the States Medical Cannabis Access for Pain Treatment Medical Cannabis in America Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit
- Join Join
The Colorado Marijuana Enforcement Division (MED) is currently soliciting public comments for proposed regulations on lab testing, product safety, production management, and other issues. The deadline to submit comments is Tuesday, September 1st.
The day before the deadline, August 31st, the MED will hold a rule-making hearing in Denver at the Colorado State Capitol Building at 9 AM (MDT) on the draft regulations.
ASA is working on finalizing our public comments, which will be made available this Friday and we would like your input for our comments. If you have concerns about the proposed regulation, please sent them to [email protected] by 6:00 PM ET on Wednesday, August 26th.
ASA strongly recommends that medical marijuana regulatory agencies base their programs on the American Herbal Products Association guidance and calibrate lab testing standards to the American Herbal Pharmacopoeia's cannabis monograph.
We look forward to your comments and using them to improve our ability bring the concerns of patients to the forefront of regulators.